New Strategies for the Management of Cystic Fibrosis and Bronchiectasis
Robert G. Masterton, FRCP (Ed), FRCPath
Department of Clinical Microbiology, Lothian University Hospitals NHS Trust, Western General Hospital, Edinburgh, Scotland, UK
Bronchiectasis and cystic fibrosis are chronic, progressive lung conditions with respiratory infections as the principal clinical feature, and the most common cause of death. Although the advent of effective antibiotics and immunizations has significantly altered the natural history of these diseases, this has, in turn, changed the pattern of infections that occur. Increasing antimicrobial resistance is a concern that is being met through the improved use of these agents and better general management of the conditions. Exciting novel therapies are on the horizon which offer the promise that cystic fibrosis in the new millennium may become a disease of the past, and the resultant impact that this will have upon the nature of bronchiectasis.